Infliximab Was Found to Be Effective for Treating Immunosuppressive Drug-resistant Hepatitis due to Durvalumab.

Abstract

A 69-year-old man with stage III lung squamous cell carcinoma developed immune-related hepatitis following treatment with durvalumab, and was given high-dose corticosteroids and immunosuppressive drugs (mycophenolate mofetil, azathioprine, tacrolimus) but without demonstrating any improvement. Two cycles of infliximab (5 mg/kg) were then administered and thereafter the hepatitis improved. At the time of writing (9 months after the initiation of first course of durvalumab), the patient is alive without either any hepatitis symptoms nor any lung cancer progression. Infliximab may be effective for treating non-small cell lung cancer (NSCLC) patients who develop immunosuppressive drug-resistant immune-related hepatitis caused by durvalumab.

• Authors: Koki Nakashima, Yoshiki Demura, Masahiro Oi, Mio Tabata, Toshihiko Tada, Kohei Shiozaki, Masaya Akai, Tamotsu Ishizuka
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 59 Issue 23 Pg. 3055-3059 (Dec 01 2020) ISSN: 1349-7235 [Electronic] Japan
• PMID: 32727989 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents, Immunological
• Immunosuppressive Agents
• durvalumab
• Infliximab
• Mycophenolic Acid
• Azathioprine

Topics

• Aged
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antineoplastic Agents, Immunological (adverse effects, therapeutic use)
• Azathioprine (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
• Chemical and Drug Induced Liver Injury (drug therapy, etiology)
• Humans
• Immunosuppressive Agents (therapeutic use)
• Infliximab (therapeutic use)
• Lung Neoplasms (drug therapy, pathology)
• Male
• Mycophenolic Acid (therapeutic use)